TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...
Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...
Copyright 2025 The Associated Press. All Rights Reserved. Tau is an investigative reporter in the Washington, D.C. bureau of the Associated Press. He focuses on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback